The Hyperhidrosis Disease Severity Scale is a validated 4-point tool where the patient picks a single statement describing how much their sweating interferes with daily activities. Scores of 1 or 2 are mild to moderate; 3 or 4 are severe.

What score is considered severe?

A score of 3 or 4. A score of 3 means sweating is barely tolerable and frequently interferes with daily activities; a score of 4 means it is intolerable and always interferes.

How much sweat reduction equals a 1-point improvement?

In the validation data, a 1-point HDSS improvement was associated with approximately a 50% reduction in gravimetrically measured sweat, and a 2-point improvement with approximately an 80% reduction.

Is the HDSS reliable?

Test-retest reliability was reported as r = 0.82, which is within the generally accepted range. HDSS scores also correlated with the DLQI and HHIQ (r = 0.35 to 0.77), suggesting the scale tracks meaningful impact.

Why do trials require an HDSS of 3 or 4 to enroll?

The 3-or-4 threshold defines patients with severe, life-interfering hyperhidrosis, the population most likely to benefit from active treatment and least likely to improve with placebo. This makes treatment effects easier to detect.

Does the HDSS replace measuring sweat?

No. The HDSS captures how sweating affects daily life; gravimetry captures how much sweat is produced. Most modern trials use both, because a treatment is generally considered successful only if it improves the HDSS and reduces measured sweat.

Research

The Hyperhidrosis Disease Severity Scale (HDSS), Explained

The Hyperhidrosis Disease Severity Scale (HDSS) is a validated, single-question, 4-point rating that turns the subjective experience of excessive sweating into a number a clinician or trial can track. It was developed and validated by Kowalski and colleagues (presented at the 2004 American Academy of Dermatology meeting) and has since become the most widely used severity endpoint in hyperhidrosis research. A score of 3 or 4 defines severe hyperhidrosis; a 1-point improvement after treatment corresponds to roughly a 50% reduction in gravimetrically measured sweat, and a 2-point improvement to roughly an 80% reduction. This page summarizes the validation data and how the scale is used. It is educational information, not medical advice.

By the Sweat Explained Editorial Team · Published 2026-07-19 · Last reviewed 2026-07-19 · Educational information, not medical advice.

Key statistics at a glance

4-point
single-question scale from 1 (never noticeable) to 4 (intolerable, always interferes)
Kowalski 2004; Solish 2007
3 or 4
HDSS score that defines severe hyperhidrosis and is the standard trial inclusion threshold
Solish 2007; FDA-registered trials
~50%
reduction in measured sweat associated with a 1-point improvement in HDSS
Kowalski 2004
~80%
reduction in measured sweat associated with a 2-point improvement in HDSS
Kowalski 2004
r = 0.82
reported test-retest reliability of the HDSS
Kowalski 2004 abstract

What the HDSS actually is

The HDSS is a single item. The patient reads four statements about how sweating interferes with daily activities and picks the one that best fits: (1) never noticeable and never interferes, (2) tolerable but sometimes interferes, (3) barely tolerable and frequently interferes, or (4) intolerable and always interferes. The chosen number is the score.

That simplicity is deliberate. The instrument was designed to be answered in seconds, without training aids, in either written or interview form, so that it could be used in a routine clinic visit and repeated to gauge treatment response. Scores of 1 or 2 are described as mild-to-moderate disease; scores of 3 or 4 are described as severe.

The four HDSS statements

The wording matters. This is the standard version used in validation studies and industry protocols.

Hyperhidrosis Disease Severity Scale, item wording
Score	Patient statement	Interpretation
1	My sweating is never noticeable and never interferes with my daily activities.	Mild
2	My sweating is tolerable but sometimes interferes with my daily activities.	Moderate
3	My sweating is barely tolerable and frequently interferes with my daily activities.	Severe
4	My sweating is intolerable and always interferes with my daily activities.	Severe

Item wording from the International Hyperhidrosis Society HDSS reference sheet (Kowalski et al., original validation).

How HDSS improvements map to measured sweat

The most clinically useful thing about the HDSS is that it was anchored to objective sweat measurement. In the validation work, improvements in HDSS after treatment tracked closely with reductions in gravimetrically measured axillary sweat.

HDSS improvement and associated reduction in gravimetric sweat

HDSS improvement and associated reduction in gravimetric sweat
Group	Value
1-point HDSS improvement	50%
2-point HDSS improvement	80%

Source: Kowalski et al., HDSS validation (2004). Chart is an original rendering of the cited data.

The validation evidence

In Kowalski's original two studies, HDSS scores at 4 weeks after treatment correlated with the Dermatology Life Quality Index (DLQI) and the Hyperhidrosis Impact Questionnaire (HHIQ), with reported correlations of r = 0.35 to 0.77 (p < 0.001). Test-retest reliability was r = 0.82. Higher HDSS scores were associated with greater self-reported interference across daily activities in a national survey, supporting the scale as a measure of impact rather than just wetness.

The instrument's responsiveness (its ability to move when a real treatment effect happens) was demonstrated by pairing HDSS change with gravimetric change: patients whose HDSS improved by 1 point had, on average, about half as much measured sweat, and those improving by 2 points had about a fifth of their pretreatment sweat. This is the anchor that turned the HDSS from an opinion poll into a trial-grade endpoint.

How the HDSS is used in clinical trials

In modern hyperhidrosis trials, a baseline HDSS of 3 or 4 is the standard inclusion criterion, because it defines the population with clinically meaningful disease. The most common primary or co-primary endpoints are (a) achieving an HDSS of 1 or 2 after treatment, (b) at least a 2-point HDSS improvement from baseline, and (c) at least a 50% reduction in gravimetric sweat. Trials of onabotulinumtoxinA, topical glycopyrronium, and topical anticholinergic wipes all use variants of these thresholds.

Regulatory reviews likewise treat a 2-point HDSS improvement (or a total HDSS score of 2 or less) as clinically meaningful. This is the operational answer to "did the treatment work?" in most published research.

What the HDSS does not do

The HDSS is powerful for its simplicity, but that simplicity has trade-offs:

It is a single question. It captures overall interference with daily life, not location, frequency, or amount of sweat.
It was validated primarily in primary axillary hyperhidrosis. Its behavior in craniofacial, plantar, or generalized secondary hyperhidrosis is less well characterized, and other scales (e.g. HDSM-Ax, ASDD) are used alongside it.
It is subjective. It is meant to complement, not replace, objective measures such as gravimetry when quantification of sweat volume matters.
It is coarse: a patient can genuinely improve without crossing a full point. Clinical trials therefore usually combine HDSS with a percent-reduction gravimetric endpoint.

Methodology and limitations

This page summarizes the original HDSS validation (Kowalski et al., presented at the American Academy of Dermatology annual meeting, 2004; abstract in J Am Acad Dermatol 2004;50(3 Suppl):P198), the International Hyperhidrosis Society reference sheet describing item wording and score interpretation, and secondary sources including Solish et al. (2007) and independent drug-class reviews that describe how the HDSS is used as an inclusion criterion and endpoint. Each numeric claim (4-point structure, 3-or-4 severe threshold, 50% and 80% anchor values, r = 0.82 test-retest, r = 0.35 to 0.77 correlations with DLQI/HHIQ) was traced to a cited source.

Limitations: the pivotal validation data appear in a published abstract and are reported consistently across secondary reviews and guideline documents rather than in a stand-alone full-text peer-reviewed article; readers who need the primary statistical detail should consult the linked abstract and secondary sources together. The scale was validated in primary axillary hyperhidrosis and is best supported in that population. Nothing on this page is medical advice; treatment thresholds and endpoints are described as they appear in the research literature.

Frequently asked questions

What is the HDSS?: The Hyperhidrosis Disease Severity Scale is a validated 4-point tool where the patient picks a single statement describing how much their sweating interferes with daily activities. Scores of 1 or 2 are mild to moderate; 3 or 4 are severe.
What score is considered severe?: A score of 3 or 4. A score of 3 means sweating is barely tolerable and frequently interferes with daily activities; a score of 4 means it is intolerable and always interferes.
How much sweat reduction equals a 1-point improvement?: In the validation data, a 1-point HDSS improvement was associated with approximately a 50% reduction in gravimetrically measured sweat, and a 2-point improvement with approximately an 80% reduction.
Is the HDSS reliable?: Test-retest reliability was reported as r = 0.82, which is within the generally accepted range. HDSS scores also correlated with the DLQI and HHIQ (r = 0.35 to 0.77), suggesting the scale tracks meaningful impact.
Why do trials require an HDSS of 3 or 4 to enroll?: The 3-or-4 threshold defines patients with severe, life-interfering hyperhidrosis, the population most likely to benefit from active treatment and least likely to improve with placebo. This makes treatment effects easier to detect.
Does the HDSS replace measuring sweat?: No. The HDSS captures how sweating affects daily life; gravimetry captures how much sweat is produced. Most modern trials use both, because a treatment is generally considered successful only if it improves the HDSS and reduces measured sweat.

Sources

Primary peer-reviewed studies and official sources first, then reviews and institutional framing (secondary).

Kowalski JW, Eadie N, Dagget S, Lai PY. Validity and reliability of the Hyperhidrosis Disease Severity Scale (HDSS). J Am Acad Dermatol. 2004;50(3 Suppl):P198 (poster P198, AAD 62nd Annual Meeting). Abstract
International Hyperhidrosis Society. Hyperhidrosis Disease Severity Scale (HDSS): item wording and clinical use. IHhS clinician reference sheet. IHhS PDF
Solish N, Bertucci V, Dansereau A, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33(8):908-923. (secondary) Full text
Naumann M, Glaser DA, Lowe NJ, et al. Treatment of hyperhidrosis with Botox (onabotulinumtoxinA): development, insights, and impact. Medicine (Baltimore). 2023;102(S1):e32764 (describes HDSS development and use in pivotal trials). (secondary) Full text
Oregon State Drug Use Research & Management. Hyperhidrosis class review: HDSS as trial endpoint and clinically meaningful thresholds. Oregon DUR/P&T Committee, April 2025. (secondary) PDF
Hornberger J, Grimes K, Naumann M, et al.; Multi-Specialty Working Group. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274-286. (secondary) Full text

How to cite this page

Sweat Explained. The Hyperhidrosis Disease Severity Scale (HDSS), Explained. Published 2026-07-19; last reviewed 2026-07-19. Available at: https://sweatexplained.com/research/hyperhidrosis-disease-severity-scale-hdss

Please cite the original studies for the underlying figures. Journalists are welcome to link to this page; the charts are original renderings of the cited data.